デフォルト表紙
市場調査レポート
商品コード
1107127

バイオ医薬品添加剤市場 - 世界の見通しと予測(2022年~2027年)

Biopharmaceutical Excipients Market - Global Outlook and Forecast 2022-2027

出版日: | 発行: Arizton Advisory & Intelligence | ページ情報: 英文 317 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
バイオ医薬品添加剤市場 - 世界の見通しと予測(2022年~2027年)
出版日: 2022年07月27日
発行: Arizton Advisory & Intelligence
ページ情報: 英文 317 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオ医薬品添加剤の市場規模は、予測期間の2022年~2027年に7.56%のCAGRで拡大すると予測されています。

当レポートでは、世界のバイオ医薬品添加剤市場について調査し、市場の概要とともに、賦形剤別、生物製剤別、事業規模別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 調査目的

第3章 調査プロセス

第4章 範囲と適用範囲

第5章 レポートの前提と注意事項

第6章 市場概要

第7章 イントロダクション

第8章 市場機会と動向

  • 医薬品開発における新規賦形剤に対する新たな需要
  • ワクチンと細胞および遺伝子治療ベースの賦形剤に対する高い需要
  • 生物製剤とバイオシミラーの豊富なパイプライン
  • バイオ医薬品の普及拡大

第9章 市場の成長促進要因

  • 癌と感染症の有病率の上昇
  • 生物製剤の製品承認数の増加
  • バイオ医薬品添加物製造のアウトソーシングに対するニーズの高まり
  • 多機能賦形剤の新たなニーズ

第10章 市場の成長抑制要因

  • バイオ医薬品添加剤の製造における規制上の課題
  • バイオ医薬品添加物に関するサプライチェーンと完全性の問題
  • バイオ医薬品添加剤の処方の課題

第11章 市場情勢

  • 市場概要
  • 市場規模と予測
    • 賦形剤別洞察
    • 生物製剤別洞察
    • 事業規模別洞察
    • エンドユーザー別洞察
    • 地域別地域
    • COVID-19の影響
  • ファイブフォース分析

第12章 賦形剤

  • 市場概要および成長促進要因
  • 市場概要
  • 増量剤
  • 可溶化剤と界面活性剤
  • 緩衝剤と張性剤
  • その他

第13章 生物製剤

  • 市場概要および成長促進要因
  • 市場概要
  • モノクローナル抗体
  • ワクチン
  • その他

第14章 運用規模

  • 市場概要および成長促進要因
  • 市場概要
  • 商業
  • 研究

第15章 エンドユーザー

  • 市場概要および成長促進要因
  • 市場概要
  • 製薬会社およびバイオテクノロジー企業
  • CMOSおよびCDMOS
  • 学術・研究機関

第16章 地域

  • 市場概要および成長促進要因
  • 地域別概要

第17章 北米

第18章 欧州

第19章 アジア太平洋

第20章 ラテンアメリカ

第21章 中東・アフリカ

第22章 競合情勢

  • 競合概要
  • 市場シェア分析

第23章 主要な企業プロファイル

  • MERCK KGAA
  • BASF SE
  • AVANTOR
  • EVONIK INDUSTRIES
  • ROQUETTE FRERES
  • ASSOCIATED BRITISH FOODS

第24章 その他の著名なベンダー

  • ACETO
  • ANGUS CHEMICAL COMPANY
  • APOTHECON PHARMACEUTICALS
  • ASHLAND
  • BIOSPECTRA
  • BOC SCIENCES
  • CG GROUP
  • CLARIANT
  • COLORCON
  • DFE PHARMA
  • DOW
  • EASTMAN CHEMICAL COMPANY
  • IMCD
  • INNOPHOS
  • INVITRIA
  • JRS PHARMA
  • KIRSCH PHARMA
  • MEGGLE
  • NOVO NORDISK
  • PFANSTIEHL
  • PHARMONIX BIOLOGICALS
  • SHIN-ETSU CHEMICAL
  • SIGACHI INDUSTRIES
  • SPECTRUM CHEMICAL
  • TEREOS
  • THE LUBRIZOL CORPORATION
  • WACKER CHEMIE

第25章 レポートの概要

第26章 定量的要約

第27章 付録

図表

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
  • EXHIBIT 3 BIOPHARMACEUTICAL CLASSIFICATION SYSTEM OF EXCIPIENTS
  • EXHIBIT 4 LIST OF EXCIPIENTS INCLUDED IN EACH BCSE CLASS
  • EXHIBIT 5 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
  • EXHIBIT 6 IMPACT OF EMERGING DEMAND FOR NOVEL EXCIPIENTS IN DRUG PRODUCT DEVELOPMENT
  • EXHIBIT 7 US FDA SOUGHT INDUSTRY INPUT ON NOVEL EXCIPIENTS
  • EXHIBIT 8 IMPACT OF HIGH DEMAND FOR VACCINES AND CELL & GENE THERAPY-BASED EXCIPIENTS
  • EXHIBIT 9 IMPACT OF EXHAUSTIVE PIPELINE OF BIOLOGICS & BIOSIMILARS
  • EXHIBIT 10 VACCINES IN PIPELINE FOR VARIOUS INFECTIOUS DISEASES
  • EXHIBIT 11 DCVMN PIPELINE: NUMBER OF VACCINE DEVELOPMENT PROJECTS (2019)
  • EXHIBIT 12 BIOSIMILARS IN DEVELOPMENT PHASES (2013 & 2020)
  • EXHIBIT 13 IMPACT OF GROWING PENETRATION OF BIOPHARMACEUTICAL DRUGS
  • EXHIBIT 14 AGGREGATE VALUE OF GLOBAL PHARMACEUTICAL INDUSTRY 2015-2020 ($ TRILLION)
  • EXHIBIT 15 IMPACT OF GROWING PREVALENCE OF CANCER & INFECTIOUS DISEASES
  • EXHIBIT 16 ESTIMATED NEW CASES OF TOP CANCERS IN 2022 (%)
  • EXHIBIT 17 REGIONAL PREVALENCE OF LEADING INFECTIOUS DISEASES
  • EXHIBIT 18 IMPACT OF RISING NUMBER OF PRODUCT APPROVALS FOR BIOLOGICS
  • EXHIBIT 19 US FDA APPROVALS OF NMES AND BIOLOGICS (2011-2020)
  • EXHIBIT 20 DEVELOPMENT OF BIOLOGIC MEDICINES BY PRODUCT CATEGORY
  • EXHIBIT 21 IMPACT OF INCREASING NEED FOR OUTSOURCING BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING
  • EXHIBIT 22 IMPACT OF EMERGING NEED FOR MULTI-FUNCTIONAL EXCIPIENTS
  • EXHIBIT 23 IMPACT OF REGULATORY CHALLENGES IN MANUFACTURING BIOPHARMACEUTICAL EXCIPIENTS
  • EXHIBIT 24 IMPACT OF SUPPLY CHAIN AND INTEGRITY ISSUES WITH BIOPHARMACEUTICAL EXCIPIENTS
  • EXHIBIT 25 IMPACT OF CHALLENGES OF FORMULATING BIOPHARMACEUTICAL EXCIPIENTS
  • EXHIBIT 26 SEARCH RESULTS OF MOST COMMONLY OCCURRING EXCIPIENTS
  • EXHIBIT 27 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 28 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY TYPE
  • EXHIBIT 29 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS
  • EXHIBIT 30 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION
  • EXHIBIT 31 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER
  • EXHIBIT 32 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY
  • EXHIBIT 33 FIVE FORCES ANALYSIS 2021
  • EXHIBIT 34 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
  • EXHIBIT 35 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT
  • EXHIBIT 36 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT: INCREMENTAL GROWTH
  • EXHIBIT 37 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT: ABSOLUTE GROWTH
  • EXHIBIT 38 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BULKING AGENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 39 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BULKING AGENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 40 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 41 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS SOLUBILIZERS & SURFACTANTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 42 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS SOLUBILIZERS & SURFACTANTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 44 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BUFFERING & TONICITY AGENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 45 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BUFFERING & TONICITY AGENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 46 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 47 GLOBAL OTHER BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 48 GLOBAL OTHER BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 49 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 50 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
  • EXHIBIT 51 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS
  • EXHIBIT 52 DISTRIBUTION OF INACTIVE INGREDIENTS IN BIOLOGIC FORMULATIONS
  • EXHIBIT 53 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS: INCREMENTAL GROWTH
  • EXHIBIT 54 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS: ABSOLUTE GROWTH
  • EXHIBIT 55 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 56 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 58 GLOBAL VACCINE EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 59 GLOBAL VACCINE EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 61 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS OTHER BIOLOGICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 62 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY OTHER BIOLOGICS 2021-2027 ($ MILLION)
  • EXHIBIT 63 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 64 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
  • EXHIBIT 65 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION
  • EXHIBIT 66 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION: INCREMENTAL GROWTH
  • EXHIBIT 67 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION: ABSOLUTE GROWTH
  • EXHIBIT 68 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 69 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 70 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 71 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 72 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 73 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 74 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 75 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER
  • EXHIBIT 76 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER: INCREMENTAL GROWTH
  • EXHIBIT 77 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER: ABSOLUTE GROWTH
  • EXHIBIT 78 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 79 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 81 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 82 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 83 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 84 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 85 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 87 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 88 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY
  • EXHIBIT 89 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: KEY COUNTRIES 2021 ($ MILLION)
  • EXHIBIT 90 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
  • EXHIBIT 91 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
  • EXHIBIT 92 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
  • EXHIBIT 93 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 94 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 95 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
  • EXHIBIT 96 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
  • EXHIBIT 97 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
  • EXHIBIT 98 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 99 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
  • EXHIBIT 100 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN US 2021-2027 ($ MILLION)
  • EXHIBIT 101 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN CANADA 2021-2027 ($ MILLION)
  • EXHIBIT 102 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
  • EXHIBIT 103 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 104 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 105 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
  • EXHIBIT 106 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
  • EXHIBIT 107 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
  • EXHIBIT 108 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 109 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
  • EXHIBIT 110 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN GERMANY 2021-2027 ($ MILLION)
  • EXHIBIT 111 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN FRANCE 2021-2027 ($ MILLION)
  • EXHIBIT 112 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN THE UK 2021-2027 ($ MILLION)
  • EXHIBIT 113 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SWITZERLAND 2021-2027 ($ MILLION)
  • EXHIBIT 114 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN ITALY 2021-2027 ($ MILLION)
  • EXHIBIT 115 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SPAIN 2021-2027 ($ MILLION)
  • EXHIBIT 116 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
  • EXHIBIT 117 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 118 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 119 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
  • EXHIBIT 120 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
  • EXHIBIT 121 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
  • EXHIBIT 122 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 123 INCREMENTAL GROWTH IN APAC 2021 & 2027
  • EXHIBIT 124 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN CHINA 2021-2027 ($ MILLION)
  • EXHIBIT 125 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN JAPAN 2021-2027 ($ MILLION)
  • EXHIBIT 126 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SOUTH KOREA 2021-2027 ($ MILLION)
  • EXHIBIT 127 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN INDIA 2021-2027 ($ MILLION)
  • EXHIBIT 128 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN AUSTRALIA 2021-2027 ($ MILLION)
  • EXHIBIT 129 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
  • EXHIBIT 130 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 131 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 132 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
  • EXHIBIT 133 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
  • EXHIBIT 134 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
  • EXHIBIT 135 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 136 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
  • EXHIBIT 137 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN BRAZIL 2021-2027 ($ MILLION)
  • EXHIBIT 138 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN MEXICO 2021-2027 ($ MILLION)
  • EXHIBIT 139 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN ARGENTINA 2021-2027 ($ MILLION)
  • EXHIBIT 140 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
  • EXHIBIT 141 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 142 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 143 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
  • EXHIBIT 144 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
  • EXHIBIT 145 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
  • EXHIBIT 146 INCREMENTAL GROWTH BY END-USER 2021 & 2027
  • EXHIBIT 147 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027
  • EXHIBIT 148 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN TURKEY 2021-2027 ($ MILLION)
  • EXHIBIT 149 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SAUDI ARABIA 2021-2027 ($ MILLION)
  • EXHIBIT 150 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN THE UAE 2021-2027 ($ MILLION)
  • EXHIBIT 151 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SOUTH AFRICA 2021-2027 ($ MILLION)
  • EXHIBIT 152 PURE AND DIVERSIFIED PLAYERS IN THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
  • EXHIBIT 153 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY VENDOR STRENGTHS & CAPABILITY ANALYSIS
  • EXHIBIT 154 POSITION OF MAJOR PLAYERS IN THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
  • EXHIBIT 155 MERCK KGAA: TOTAL REVENUE 2019-2021 ($ MILLION)
  • EXHIBIT 156 MERCK KGAA: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
  • EXHIBIT 157 MERCK KGAA: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
  • EXHIBIT 158 MERCK KGAA: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
  • EXHIBIT 159 BASF: TOTAL REVENUE 2019-2021 ($ MILLION)
  • EXHIBIT 160 BASF: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
  • EXHIBIT 161 BASF: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
  • EXHIBIT 162 BASF: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
  • EXHIBIT 163 AVANTOR: TOTAL REVENUE 2019-2021 ($ MILLION)
  • EXHIBIT 164 AVANTOR: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
  • EXHIBIT 165 AVANTOR: REVENUE BY PRODUCT LINE 2019-2021 ($ MILLION)
  • EXHIBIT 166 EVONIK INDUSTRIES: TOTAL REVENUE 2019-2021 ($ MILLION)
  • EXHIBIT 167 EVONIK INDUSTRIES: REVENUE BY SEGMENT 2020-2021 ($ MILLION)
  • EXHIBIT 168 EVONIK INDUSTRIES: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
  • EXHIBIT 169 EVONIK INDUSTRIES: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
  • EXHIBIT 170 ASSOCIATED BRITISH FOODS: TOTAL REVENUE 2019-2021 ($ MILLION)
  • EXHIBIT 171 ASSOCIATED BRITISH FOODS: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
  • EXHIBIT 172 ASSOCIATED BRITISH FOODS: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
  • EXHIBIT 173 ASSOCIATED BRITISH FOODS: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
  • EXHIBIT 174 MEGGLE: MAJOR PRODUCT OFFERINGS
  • EXHIBIT 175 PFANSTIEHL: MAJOR PRODUCT OFFERINGS

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2021
  • TABLE 3 EXCIPIENTS USED IN BIOPHARMACEUTICAL FORMULATIONS & THEIR EFFECTS
  • TABLE 4 CATEGORIES AND EXAMPLES OF SOME BIOPHARMACEUTICAL EXCIPIENTS IN FORMULATING VACCINES
  • TABLE 5 EXAMPLES OF EXCIPIENTS IN US LICENSED CELL & GENE THERAPY PRODUCTS
  • TABLE 6 PERCENTAGE SHARE OF VARIOUS BIOPHARMACEUTICALS WITH SMALL MOLECULES 2015 & 2020
  • TABLE 7 TOTAL REVENUE SHARE OF BIOPHARMACEUTICALS AMONG TOP PHARMACEUTICAL COMPANIES (2012)
  • TABLE 8 MERCK KGAA: MAJOR PRODUCT OFFERINGS
  • TABLE 9 BASF: MAJOR PRODUCT OFFERINGS
  • TABLE 10 AVANTOR: MAJOR PRODUCT OFFERINGS
  • TABLE 11 EVONIK INDUSTRIES: MAJOR PRODUCT OFFERINGS
  • TABLE 12 ROQUETTE FRERES: MAJOR PRODUCT OFFERINGS
  • TABLE 13 ASSOCIATED BRITISH FOODS: MAJOR PRODUCT OFFERINGS
  • TABLE 14 ACETO: MAJOR PRODUCT OFFERINGS
  • TABLE 15 ANGUS CHEMICAL COMPANY: MAJOR PRODUCT OFFERINGS
  • TABLE 16 APOTHECON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 17 ASHLAND: MAJOR PRODUCT OFFERINGS
  • TABLE 18 BIOSPECTRA: MAJOR PRODUCT OFFERINGS
  • TABLE 19 BOC SCIENCES: MAJOR PRODUCT OFFERINGS
  • TABLE 20 CG GROUP: MAJOR PRODUCT OFFERINGS
  • TABLE 21 CLARIANT: MAJOR PRODUCT OFFERINGS
  • TABLE 22 COLORCON: MAJOR PRODUCT OFFERINGS
  • TABLE 23 DFE PHARMA: MAJOR PRODUCT OFFERINGS
  • TABLE 24 DOW: MAJOR PRODUCT OFFERINGS
  • TABLE 25 EASTMAN CHEMICAL COMPANY: MAJOR PRODUCT OFFERINGS
  • TABLE 26 IMCD: MAJOR PRODUCT OFFERINGS
  • TABLE 27 INNOPHOS: MAJOR PRODUCT OFFERINGS
  • TABLE 28 INVITRIA: MAJOR PRODUCT OFFERINGS
  • TABLE 29 JRS PHARMA: MAJOR PRODUCT OFFERINGS
  • TABLE 30 KIRSCH PHARMA: MAJOR PRODUCT OFFERINGS
  • TABLE 31 NOVO NORDISK: MAJOR PRODUCT OFFERINGS
  • TABLE 32 PHARMONIX BIOLOGICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 33 SHIN-ETSU CHEMICAL: MAJOR PRODUCT OFFERINGS
  • TABLE 34 SIGACHI INDUSTRIES: MAJOR PRODUCT OFFERINGS
  • TABLE 35 SPECTRUM CHEMICAL: MAJOR PRODUCT OFFERINGS
  • TABLE 36 TEREOS: MAJOR PRODUCT OFFERINGS
  • TABLE 37 THE LUBRIZOL CORPORATION: MAJOR PRODUCT OFFERINGS
  • TABLE 38 WACKER CHEMIE: MAJOR PRODUCT OFFERINGS
  • TABLE 39 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 ($ MILLION)
  • TABLE 40 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 (%)
  • TABLE 41 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 ($ MILLION)
  • TABLE 42 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 (%)
  • TABLE 43 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 ($ MILLION)
  • TABLE 44 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 (%)
  • TABLE 45 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 ($ MILLION)
  • TABLE 46 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 (%)
  • TABLE 47 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 ($ MILLION)
  • TABLE 48 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 (%)
  • TABLE 49 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 ($ MILLION)
  • TABLE 50 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021-2027 (%)
  • TABLE 51 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • TABLE 52 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 (%)
  • TABLE 53 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • TABLE 54 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 (%)
  • TABLE 55 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • TABLE 56 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 (%)
  • TABLE 57 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • TABLE 58 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 (%)
  • TABLE 59 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • TABLE 60 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 (%)
  • TABLE 61 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 ($ MILLION)
  • TABLE 62 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021-2027 (%)
  • TABLE 63 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 ($ MILLION)
  • TABLE 64 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 (%)
  • TABLE 65 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 ($ MILLION)
  • TABLE 66 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 (%)
  • TABLE 67 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 ($ MILLION)
  • TABLE 68 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 (%)
  • TABLE 69 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 ($ MILLION)
  • TABLE 70 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 (%)
  • TABLE 71 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 ($ MILLION)
  • TABLE 72 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 (%)
  • TABLE 73 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 ($ MILLION)
  • TABLE 74 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021-2027 (%)
  • TABLE 75 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 76 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 (%)
  • TABLE 77 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 78 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 (%)
  • TABLE 79 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 80 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 (%)
  • TABLE 81 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 82 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 (%)
  • TABLE 83 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 84 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 (%)
  • TABLE 85 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021-2027 (%)
  • TABLE 87 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 88 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 89 GLOBAL BIOPHARMACEUTICAL BULKING AGENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 90 GLOBAL BIOPHARMACEUTICAL BULKING AGENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 91 GLOBAL BIOPHARMACEUTICAL SOLUBILIZERS & SURFACTANTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 92 GLOBAL BIOPHARMACEUTICAL SOLUBILIZERS & SURFACTANTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 93 GLOBAL BIOPHARMACEUTICAL BUFFERING & TONICITY AGENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 94 GLOBAL BIOPHARMACEUTICAL BUFFERING & TONICITY AGENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 95 GLOBAL BIOPHARMACEUTICAL OTHER EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 96 GLOBAL BIOPHARMACEUTICAL OTHER EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 97 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 98 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 99 GLOBAL VACCINE EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 100 GLOBAL VACCINE EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 101 GLOBAL OTHER BIOLOGICS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 102 GLOBAL OTHER BIOLOGICS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 103 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 104 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 105 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 106 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 107 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 108 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 109 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 110 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 111 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 112 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2021-2027 (%)
目次
Product Code: ARZ220620

The global biopharmaceutical excipients market is expected to grow at a CAGR of 7.56% during 2022-2027.

Excipients are fundamental components of any biopharmaceutical drug product, which act as active ingredients, stability enhancers, emulsifying and suspending agents, binders, preservatives, antioxidants, and lubricants. These differ from prodrugs in manufacturing or are present in a finished pharmaceutical product dosage form. Excipients have targeted roles, ranging from protecting the API to easing the manufacturing process, which, in turn, drives the need and stipulation of excipients for developing effective formulations.

The constant shift of trends in the pharma sector, including new drug development, continuous manufacturing, and innovative drug technologies, has donated to a surge in demand for excipients with advanced functions. Between 40-70% of marketed drugs and up to 90% of all new chemical entities (NCEs) registered to suffer from poor water solubility. This can have significant negative consequences on the bioavailability of the active pharmaceutical ingredient (API), potentially impacting the therapeutic effect. The market for solubility-enhancing excipients and related technologies is proliferating to tackle the problem.

High-concentration biologic formulations account for an increasing percentage of the drug development pipeline as drug manufacturers seek to offer advanced therapeutics that the patient or caregiver can administer in the home setting. These high concentrations include protein-protein interactions due to higher viscosities. Excipients can help minimize these interactions without negatively impacting protein stability and other aspects of biologic formulations. This is driving a shift towards carefully selected combinations of viscosity-reducing excipients.

Biologics- Pipeline and Product Approvals, a Major driver for Biopharmaceutical Excipients Market

With a growing number of infectious diseases and cancers, there is a high demand for various biologic drugs. Innovative biopharmaceutical companies are continuously operating with stakeholders across the R&D landscape for the expansion of newer ways to treat such diseases. To date, 258 vaccines are in the pipeline for treating and preventing severe infectious diseases. According to a study, trends in global vaccine R&D found that the proportion of new vaccine candidates entering all stages of clinical development increased by 3-5 percentage points over the past two decades. Small and medium-sized companies accounted for nearly twice as many new Phase I vaccine trials as large companies, but large companies dominated late-stage (Phase III) vaccine trials.

The biologics industry is increasing, with an estimated 40% of biopharmaceuticals in the industry pipeline. Biological products are the fastest-growing class of therapeutic products, especially in the U.S. Since 2000, more than 475 new prescription medicines (new molecular entities (NMEs) and new biologics license applications) have been approved for use by the U.S. Food and Drug Administration. The growing approvals of biopharmaceuticals will likely increase the need for novel excipients used in their formulation and contribute to market growth.

Novel Excipients Creating a Major Shift from Traditional Excipients

As drug substances become increasingly complex, formulation challenges will continue to grow. Novel excipients can significantly impact drug development and, by extension, the number and types of treatments available to patients. A novel excipient differs from an excipient in that it has not been previously used in an approved drug. In an essential step for modernizing drug formulation and biopharmaceutical development, FDA is launching a program to test the safety and suitability of novel inactive ingredients for use in new drugs and biologics. The aim is to encourage sponsors of clinical trials to formulate innovative therapies with those new excipients that FDA finds acceptable for use under this program.

Growing Trend Outsourcing the Manufacture of Biopharmaceutical Excipients

In today's market, pharmaceutical companies cite improved quality and faster time to market as the main reasons for outsourcing business functions to contract research organizations (CROs) and contract development and research organizations (CDMOs). Formulators are increasingly facing complexity with ingredients in their drug products and incorporating multiple active elements, increasing regulations, changing social and consumer preferences, and environmental implications impact production and eventual decomposition. This led to the outsourcing of ingredients manufacturing which also includes excipients as a significant component.

Challenges Restraining the Growth of Biopharmaceutical Excipients

The quality and safety of pharmaceutical products are the top concerns of regulators. In recent years, regulatory agencies have strengthened their position on preventing drug adulteration in active pharmaceutical ingredients (API) and excipients by enacting new regulations. However, the current regulatory landscape or lack of an independent excipient approval pathway can limit the entrance of new excipients into the market and, subsequently, new drug products.

Many challenges are associated with excipient quality management, managing extended supply chains, and developing certification schemes for producing and supplying excipients. Not satisfactorily meeting these challenges creates the potential for counterfeit or substandard excipients to enter the supply chain. Furthermore, several challenges also exist in formulating biological drug products using excipients due to the complexity and fragility of the active compounds.

Impact of COVID-19 on Biopharmaceutical Excipients

During the pandemic, companies rushed to develop new biopharmaceuticals, drug products, vaccines, and re-purpose older drug products. Due to this, the importance of the critical function excipients in these products has risen. Excipients played a vital role in the progression of new biopharmaceuticals, pharmaceuticals, and vaccines to fight COVID-19 and other diseases. Therefore, various excipients are required to stabilize biologics and vaccines during processing and storage. Selection and use of the appropriate excipients enabled the development of novel therapies and robust pharmaceutical products.

By Excipient

The global biopharmaceutical excipients market is segmented by bulking agents, solubilizers & surfactants, buffering & tonicity agents, and others. In 2021, bulking agents accounted for the highest share of 39% and were expected to have the most significant incremental growth during the forecast period.

By Biologics

Biologics included monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapy, interferons, growth factors, and others. In 2021, monoclonal antibodies accounted for the highest share of 45.04% and were expected to have the most significant incremental growth during the forecast period. A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to an individual parent cell. Monoclonal antibodies can have monovalent affinity, binding only to the same epitope (the part of an antigen recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different antibody-secreting plasma cell lineages. Bispecific monoclonal antibodies can also be engineered by increasing the therapeutic targets of one monoclonal antibody to two epitopes.

Vaccines are inherently less stable than small molecules, and formulation development is often challenging with stringent product development timelines. Their complex molecular structure, lack of well-defined stability-indicating assays, and a multitude of degradation mechanisms create significant hurdles for the formulation development of vaccines.

By Scale of Operation

The global biopharmaceutical excipients market is segmented by commercial and research. In 2021, retail accounted for the highest share of 73.20% and was expected to grow with the highest incremental and absolute growth of $862.44 million and 56.60%, respectively, during the forecast period.

With growing infectious diseases and the onset of epidemics and pandemics, there is a massive demand for manufacturing a billion doses of biologics within months. With a greater uptake of biologics, the need for manufacturing high quantities of these drugs is increasing. Biopharmaceutical manufacturing large-scale drug substances and products is a highly challenging task. With a high patient population in the commercial phase, the rapid development of large-scale production is a critical step that requires enormous volumes of ingredients.

By End-user

The global biopharmaceutical excipients market is segmented by pharma & biotech companies, CMOs & CDMOs, and academic & research institutes. In 2021, pharma & biotech companies accounted for the highest share of 57.63% and were expected to have the most significant incremental growth of $640.83 million during the forecast period.

With growing infectious diseases and the onset of epidemics and pandemics, there is a massive demand for manufacturing a billion doses of biologics within months. With a greater uptake of biologics, the need for manufacturing high quantities of these drugs is increasing. Biopharmaceutical manufacturing large-scale drug substances and products is a highly challenging task. With a high patient population in the commercial phase, the rapid development of large-scale production is a critical step that requires enormous volumes of ingredients.

By Geography

In 2021, North America dominated the global biopharmaceutical excipients market with 34.10%. However, APAC is likely the fastest-growing region in the worldwide biopharmaceutical excipients market, with the highest CAGR of 9.01% during the forecast period. The North American biopharmaceuticals market is well established, with prominent biopharmaceutical manufacturing companies based in the region. The rise in drug development has significantly increased the demand for biopharmaceutical excipients in this region. The US is the major revenue contributor in North America mainly due to an increase in the vaccine market, reflecting the growth in awareness of vaccinations and their benefits against infectious diseases.

Increasing populations, the emergence of infections, demand for vaccines, improved biopharma facilities, and the advent of COVID-19 are significant factors boosting the demand for biopharmaceutical excipients in Europe. However, APAC is the fastest-growing region for biopharmaceutical excipients. Emerging countries such as China and Japan are the major players due to low labor costs and increased outsourcing of inorganic and organic chemicals manufacturing. Latin America, the Middle East, & Africa accounted for minor shares in the global biopharmaceutical excipients market.

COMPETITIVE LANDSCAPE

The global biopharmaceutical excipients market is fragmented, with vendors ranging from emerging mid-sized to established players contributing to its revenue. Most of the leading players focus on implementing various strategies such as product launches and approvals, marketing, and promotional activities, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market. For instance, in 2020, DFE Pharma launched a new portfolio of biopharmaceutical excipients for stabilizing biologics to capitalize on increasing growth in the biologics sector. In the same year, MilliporeSigma agreed with ReForm Biologics to commercialize ReForm's excipients used in biotherapeutic formulations.

Established players that accounted for a significant share in the global biopharmaceutical excipients market include Merck KGaA, DFE Pharma, Avantor, BASF SE, Evonik Industries AG, and Rouquette Freres. Other prominent vendors that are emerging in the global biopharmaceutical excipients market are Aceto, Ashland Global Holdings, Biohale, Biospectra, Clariant, Colorcon, Dow Chemical Industries, Fuji Chemical Industries, IMCD, Innophos, JRS Pharma, Kirsch Pharma, Novo Nordisk, Pfanstiehl, Pharmonix Biologicals, Sigachi Industries.

Vendors

  • Merck KGAA
  • BASF SE
  • Avantor
  • Evonik Industries
  • Roquette Freres

Other Prominent Vendors

  • Aceto
  • Angus Chemical
  • Apothecon
  • Ashland Global
  • BioSpectra
  • BOC Sciences
  • C.G. Group
  • Clariant
  • Colorcon
  • DFE Pharma
  • DOW
  • Eastman Chemical
  • IMCD N.V.
  • Innophos
  • Invitria
  • JRS Pharma
  • Kirsch Pharma
  • Meggle
  • Novo Nordisk
  • PFANSTIEHL
  • Pharmonix
  • Shin-Etsu Chemical
  • Sigachi Industries
  • Spectrum Chemical
  • Tereos
  • The Lubrizol
  • Wacker Chemie

KEY QUESTIONS ANSWERED

  • 1. HOW BIG IS THE BIOPHARMACEUTICAL EXCIPIENTS MARKET?
  • 2. WHAT IS THE BIOPHARMACEUTICAL EXCIPIENTS MARKET GROWTH?
  • 3. WHO ARE THE MARKET LEADERS IN THE GLOBAL BIOPHARMACEUTICAL INDUSTRY?
  • 4. WHAT ARE THE TOP TRENDS DRIVING THE MARKET GROWTH?

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY EXCIPIENT
    • 4.3.2 MARKET SEGMENTATION BY BIOLOGICS
    • 4.3.3 MARKET SEGMENTATION BY SCALE OF OPERATION
    • 4.3.4 MARKET SEGMENTATION BY END-USER
    • 4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 OVERVIEW
  • 7.2 MARKET SYNOPSIS
    • 7.2.1 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SCENARIO
    • 7.2.2 BIOLOGICS - PIPELINE AND PRODUCT APPROVALS, A MAJOR DRIVER FOR BIOPHARMACEUTICAL EXCIPIENTS
    • 7.2.3 NOVEL EXCIPIENTS CREATING A MAJOR SHIFT FROM TRADITIONAL EXCIPIENTS
    • 7.2.4 GROWING TREND OF OUTSOURCING THE MANUFACTURE OF BIOPHARMACEUTICAL EXCIPIENTS
    • 7.2.5 CHALLENGES RESTRAINING THE GROWTH OF BIOPHARMACEUTICAL EXCIPIENTS
    • 7.2.6 IMPACT OF COVID-19 ON BIOPHARMACEUTICAL EXCIPIENTS
    • 7.2.7 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS: MARKET SEGMENTATIONS
    • 7.2.8 COMPETITIVE LANDSCAPE

8 MARKET OPPORTUNITIES & TRENDS

  • 8.1 EMERGING DEMAND FOR NOVEL EXCIPIENTS IN DRUG PRODUCT DEVELOPMENT
  • 8.2 HIGH DEMAND FOR VACCINES AND CELL & GENE THERAPY-BASED EXCIPIENTS
  • 8.3 EXHAUSTIVE PIPELINE OF BIOLOGICS & BIOSIMILARS
  • 8.4 GROWING PENETRATION OF BIOPHARMACEUTICAL DRUGS

9 MARKET GROWTH ENABLERS

  • 9.1 GROWING PREVALENCE OF CANCER AND INFECTIOUS DISEASES
  • 9.2 RISING NUMBER OF PRODUCT APPROVALS FOR BIOLOGICS
  • 9.3 INCREASING NEED FOR OUTSOURCING BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING
  • 9.4 EMERGING NEED FOR MULTI-FUNCTIONAL EXCIPIENTS

10 MARKET RESTRAINTS

  • 10.1 REGULATORY CHALLENGES IN MANUFACTURING BIOPHARMACEUTICAL EXCIPIENTS
  • 10.2 SUPPLY CHAIN AND INTEGRITY ISSUES WITH BIOPHARMACEUTICAL EXCIPIENTS
  • 10.3 CHALLENGES OF FORMULATING BIOPHARMACEUTICAL EXCIPIENTS

11 MARKET LANDSCAPE

  • 11.1 MARKET OVERVIEW
  • 11.2 MARKET SIZE & FORECAST
    • 11.2.1 INSIGHTS BY EXCIPIENT
    • 11.2.2 INSIGHTS BY BIOLOGICS
    • 11.2.3 INSIGHTS BY SCALE OF OPERATION
    • 11.2.4 INSIGHTS BY END-USERS
    • 11.2.5 INSIGHTS BY GEOGRAPHY
    • 11.2.6 IMPACT OF COVID-19
  • 11.3 FIVE FORCES ANALYSIS
    • 11.3.1 THREAT OF NEW ENTRANTS
    • 11.3.2 BARGAINING POWER OF SUPPLIERS
    • 11.3.3 BARGAINING POWER OF BUYERS
    • 11.3.4 THREAT OF SUBSTITUTES
    • 11.3.5 COMPETITIVE RIVALRY

12 EXCIPIENT

  • 12.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 12.2 MARKET OVERVIEW
  • 12.3 BULKING AGENTS
    • 12.3.1 MARKET OVERVIEW
    • 12.3.2 MARKET SIZE & FORECAST
    • 12.3.3 BULKING AGENTS: GEOGRAPHY SEGMENTATION
  • 12.4 SOLUBILIZERS & SURFACTANTS
    • 12.4.1 MARKET OVERVIEW
    • 12.4.2 MARKET SIZE & FORECAST
    • 12.4.3 SOLUBILIZERS & SURFACTANTS: GEOGRAPHY SEGMENTATION
  • 12.5 BUFFERING & TONICITY AGENTS
    • 12.5.1 MARKET OVERVIEW
    • 12.5.2 MARKET SIZE & FORECAST
    • 12.5.3 BUFFERING & TONICITY AGENTS: GEOGRAPHY SEGMENTATION
  • 12.6 OTHERS
    • 12.6.1 MARKET OVERVIEW
    • 12.6.2 MARKET SIZE & FORECAST
    • 12.6.3 OTHERS: GEOGRAPHY SEGMENTATION

13 BIOLOGICS

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 MONOCLONAL ANTIBODIES
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 MONOCLONAL ANTIBODIES: GEOGRAPHY SEGMENTATION
  • 13.4 VACCINES
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 VACCINES: GEOGRAPHY SEGMENTATION
  • 13.5 OTHERS
    • 13.5.1 MARKET OVERVIEW
    • 13.5.2 MARKET SIZE & FORECAST
    • 13.5.3 OTHERS: GEOGRAPHY SEGMENTATION

14 SCALE OF OPERATION

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 COMMERCIAL
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 COMMERCIAL: GEOGRAPHY SEGMENTATION
  • 14.4 RESEARCH
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 RESEARCH: GEOGRAPHY SEGMENTATION

15 END-USER

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 PHARMA & BIOTECH COMPANIES
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
  • 15.4 CMOS & CDMOS
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 CMOS & CDMOS: GEOGRAPHY SEGMENTATION
  • 15.5 ACADEMIC & RESEARCH INSTITUTES
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
    • 15.5.3 ACADEMIC & RESEARCH INSTITUTES: GEOGRAPHY SEGMENTATION

16 GEOGRAPHY

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
    • 17.2.1 NORTH AMERICA: EXCIPIENT
    • 17.2.2 NORTH AMERICA: BIOLOGICS
    • 17.2.3 NORTH AMERICA: SCALE OF OPERATION
    • 17.2.4 NORTH AMERICA: END-USER
  • 17.3 KEY COUNTRIES
    • 17.3.1 US: MARKET SIZE & FORECAST
    • 17.3.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
    • 18.2.1 EUROPE: EXCIPIENT
    • 18.2.2 EUROPE: BIOLOGICS
    • 18.2.3 EUROPE: SCALE OF OPERATION
    • 18.2.4 EUROPE: END-USER
  • 18.3 KEY COUNTRIES
    • 18.3.1 GERMANY: MARKET SIZE & FORECAST
    • 18.3.2 FRANCE: MARKET SIZE & FORECAST
    • 18.3.3 UK: MARKET SIZE & FORECAST
    • 18.3.4 SWITZERLAND: MARKET SIZE & FORECAST
    • 18.3.5 ITALY: MARKET SIZE & FORECAST
    • 18.3.6 SPAIN: MARKET SIZE & FORECAST

19 APAC

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
    • 19.2.1 APAC: EXCIPIENT
    • 19.2.2 APAC: BIOLOGICS
    • 19.2.3 APAC: SCALE OF OPERATION
    • 19.2.4 APAC: END-USER
  • 19.3 KEY COUNTRIES
    • 19.3.1 CHINA: MARKET SIZE & FORECAST
    • 19.3.2 JAPAN: MARKET SIZE & FORECAST
    • 19.3.3 SOUTH KOREA: MARKET SIZE & FORECAST
    • 19.3.4 INDIA: MARKET SIZE & FORECAST
    • 19.3.5 AUSTRALIA: MARKET SIZE & FORECAST

20 LATIN AMERICA

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
    • 20.2.1 LATIN AMERICA: EXCIPIENT
    • 20.2.2 LATIN AMERICA: BIOLOGICS
    • 20.2.3 LATIN AMERICA: SCALE OF OPERATION
    • 20.2.4 LATIN AMERICA: END-USER
  • 20.3 KEY COUNTRIES
    • 20.3.1 BRAZIL: MARKET SIZE & FORECAST
    • 20.3.2 MEXICO: MARKET SIZE & FORECAST
    • 20.3.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
    • 21.2.1 MIDDLE EAST & AFRICA: EXCIPIENT
    • 21.2.2 MIDDLE EAST & AFRICA: BIOLOGICS
    • 21.2.3 MIDDLE EAST & AFRICA: SCALE OF OPERATION
    • 21.2.4 MIDDLE EAST & AFRICA: END-USER
  • 21.3 KEY COUNTRIES
    • 21.3.1 TURKEY: MARKET SIZE & FORECAST
    • 21.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
    • 21.3.3 UAE: MARKET SIZE & FORECAST
    • 21.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

  • 22.1 COMPETITION OVERVIEW
  • 22.2 MARKET SHARE ANALYSIS
    • 22.2.1 MERCK KGAA
    • 22.2.2 BASF SE
    • 22.2.3 AVANTOR
    • 22.2.4 EVONIK INDUSTRIES
    • 22.2.5 ROQUETTE FRERES
    • 22.2.6 ASSOCIATED BRITISH FOODS

23 KEY COMPANY PROFILES

  • 23.1 MERCK KGAA
    • 23.1.1 BUSINESS OVERVIEW
    • 23.1.2 PRODUCT OFFERINGS
    • 23.1.3 KEY STRATEGIES
    • 23.1.4 KEY STRENGTHS
    • 23.1.5 KEY OPPORTUNITIES
  • 23.2 BASF SE
    • 23.2.1 BUSINESS OVERVIEW
    • 23.2.2 PRODUCT OFFERINGS
    • 23.2.3 KEY STRATEGIES
    • 23.2.4 KEY STRENGTHS
    • 23.2.5 KEY OPPORTUNITIES
  • 23.3 AVANTOR
    • 23.3.1 BUSINESS OVERVIEW
    • 23.3.2 PRODUCT OFFERINGS
    • 23.3.3 KEY STRATEGIES
    • 23.3.4 KEY STRENGTHS
    • 23.3.5 KEY OPPORTUNITIES
  • 23.4 EVONIK INDUSTRIES
    • 23.4.1 BUSINESS OVERVIEW
    • 23.4.2 PRODUCT OFFERINGS
    • 23.4.3 KEY STRATEGIES
    • 23.4.4 KEY STRENGTHS
    • 23.4.5 KEY OPPORTUNITIES
  • 23.5 ROQUETTE FRERES
    • 23.5.1 BUSINESS OVERVIEW
    • 23.5.2 PRODUCT OFFERINGS
    • 23.5.3 KEY STRATEGIES
    • 23.5.4 KEY STRENGTHS
    • 23.5.5 KEY OPPORTUNITIES
  • 23.6 ASSOCIATED BRITISH FOODS
    • 23.6.1 BUSINESS OVERVIEW
    • 23.6.2 PRODUCT OFFERINGS
    • 23.6.3 KEY STRATEGIES
    • 23.6.4 KEY STRENGTHS
    • 23.6.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

  • 24.1 ACETO
    • 24.1.1 BUSINESS OVERVIEW
    • 24.1.2 PRODUCT OFFERINGS
  • 24.2 ANGUS CHEMICAL COMPANY
    • 24.2.1 BUSINESS OVERVIEW
    • 24.2.2 PRODUCT OFFERINGS
  • 24.3 APOTHECON PHARMACEUTICALS
    • 24.3.1 BUSINESS OVERVIEW
    • 24.3.2 PRODUCT OFFERINGS
  • 24.4 ASHLAND
    • 24.4.1 BUSINESS OVERVIEW
    • 24.4.2 PRODUCT OFFERINGS
  • 24.5 BIOSPECTRA
    • 24.5.1 BUSINESS OVERVIEW
    • 24.5.2 PRODUCT OFFERINGS
  • 24.6 BOC SCIENCES
    • 24.6.1 BUSINESS OVERVIEW
    • 24.6.2 PRODUCT OFFERINGS
  • 24.7 CG GROUP
    • 24.7.1 BUSINESS OVERVIEW
    • 24.7.2 PRODUCT OFFERINGS
  • 24.8 CLARIANT
    • 24.8.1 BUSINESS OVERVIEW
    • 24.8.2 PRODUCT OFFERINGS
  • 24.9 COLORCON
    • 24.9.1 BUSINESS OVERVIEW
    • 24.9.2 PRODUCT OFFERINGS
  • 24.10 DFE PHARMA
    • 24.10.1 BUSINESS OVERVIEW
    • 24.10.2 PRODUCT OFFERINGS
  • 24.11 DOW
    • 24.11.1 BUSINESS OVERVIEW
    • 24.11.2 PRODUCT OFFERINGS
  • 24.12 EASTMAN CHEMICAL COMPANY
    • 24.12.1 BUSINESS OVERVIEW
    • 24.12.2 PRODUCT OFFERINGS
  • 24.13 IMCD
    • 24.13.1 BUSINESS OVERVIEW
    • 24.13.2 PRODUCT OFFERINGS
  • 24.14 INNOPHOS
    • 24.14.1 BUSINESS OVERVIEW
    • 24.14.2 PRODUCT OFFERINGS
  • 24.15 INVITRIA
    • 24.15.1 BUSINESS OVERVIEW
    • 24.15.2 PRODUCT OFFERINGS
  • 24.16 JRS PHARMA
    • 24.16.1 BUSINESS OVERVIEW
    • 24.16.2 PRODUCT OFFERINGS
  • 24.17 KIRSCH PHARMA
    • 24.17.1 BUSINESS OVERVIEW
    • 24.17.2 PRODUCT OFFERINGS
  • 24.18 MEGGLE
    • 24.18.1 BUSINESS OVERVIEW
    • 24.18.2 PRODUCT OFFERINGS
  • 24.19 NOVO NORDISK
    • 24.19.1 BUSINESS OVERVIEW
    • 24.19.2 PRODUCT OFFERINGS
  • 24.20 PFANSTIEHL
    • 24.20.1 BUSINESS OVERVIEW
    • 24.20.2 PRODUCT OFFERINGS
  • 24.21 PHARMONIX BIOLOGICALS
    • 24.21.1 BUSINESS OVERVIEW
    • 24.21.2 PRODUCT OFFERINGS
  • 24.22 SHIN-ETSU CHEMICAL
    • 24.22.1 BUSINESS OVERVIEW
    • 24.22.2 PRODUCT OFFERINGS
  • 24.23 SIGACHI INDUSTRIES
    • 24.23.1 BUSINESS OVERVIEW
    • 24.23.2 PRODUCT OFFERINGS
  • 24.24 SPECTRUM CHEMICAL
    • 24.24.1 BUSINESS OVERVIEW
    • 24.24.2 PRODUCT OFFERINGS
  • 24.25 TEREOS
    • 24.25.1 BUSINESS OVERVIEW
    • 24.25.2 PRODUCT OFFERINGS
  • 24.26 THE LUBRIZOL CORPORATION
    • 24.26.1 BUSINESS OVERVIEW
    • 24.26.2 PRODUCT OFFERINGS
  • 24.27 WACKER CHEMIE
    • 24.27.1 BUSINESS OVERVIEW
    • 24.27.2 PRODUCT OFFERINGS

25 REPORT SUMMARY

  • 25.1 KEY TAKEAWAYS
  • 25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

  • 26.1 EXCIPIENT
    • 26.1.1 NORTH AMERICA: EXCIPIENT SEGMENTATION
    • 26.1.2 EUROPE: EXCIPIENT SEGMENTATION
    • 26.1.3 APAC: EXCIPIENT SEGMENTATION
    • 26.1.4 LATIN AMERICA: EXCIPIENT SEGMENTATION
    • 26.1.5 MIDDLE EAST & AFRICA: EXCIPIENT SEGMENTATION
  • 26.2 BIOLOGICS
    • 26.2.1 NORTH AMERICA: BIOLOGICS SEGMENTATION
    • 26.2.2 EUROPE: BIOLOGICS SEGMENTATION
    • 26.2.3 APAC: BIOLOGICS SEGMENTATION
    • 26.2.4 LATIN AMERICA: BIOLOGICS SEGMENTATION
    • 26.2.5 MIDDLE EAST & AFRICA: BIOLOGICS SEGMENTATION
  • 26.3 SCALE OF OPERATION
    • 26.3.1 NORTH AMERICA: SCALE OF OPERATION SEGMENTATION
    • 26.3.2 EUROPE: SCALE OF OPERATION SEGMENTATION
    • 26.3.3 APAC: SCALE OF OPERATION SEGMENTATION
    • 26.3.4 LATIN AMERICA: SCALE OF OPERATION SEGMENTATION
    • 26.3.5 MIDDLE EAST & AFRICA: SCALE OF OPERATION SEGMENTATION
  • 26.4 END-USER
    • 26.4.1 NORTH AMERICA: END-USER SEGMENTATION
    • 26.4.2 EUROPE: END-USER SEGMENTATION
    • 26.4.3 APAC: END-USER SEGMENTATION
    • 26.4.4 LATIN AMERICA: END-USER SEGMENTATION
    • 26.4.5 MIDDLE EAST & AFRICA: END-USER SEGMENTATION
  • 26.5 GEOGRAPHY
    • 26.5.1 BULKING AGENTS: GEOGRAPHY SEGMENTATION
    • 26.5.2 SOLUBILIZERS & SURFACTANTS: GEOGRAPHY SEGMENTATION
    • 26.5.3 BUFFERING & TONICITY AGENTS: GEOGRAPHY SEGMENTATION
    • 26.5.4 OTHER EXCIPIENTS: GEOGRAPHY SEGMENTATION
    • 26.5.5 MONOCLONAL ANTIBODIES: GEOGRAPHY SEGMENTATION
    • 26.5.6 VACCINES: GEOGRAPHY SEGMENTATION
    • 26.5.7 OTHER BIOLOGICS: GEOGRAPHY SEGMENTATION
    • 26.5.8 COMMERCIAL: GEOGRAPHY SEGMENTATION
    • 26.5.9 RESEARCH: GEOGRAPHY SEGMENTATION
    • 26.5.10 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
    • 26.5.11 CMOS & CDMOS: GEOGRAPHY SEGMENTATION
    • 26.5.12 ACADEMIC & RESEARCH INSTITUTES: GEOGRAPHY SEGMENTATION

27 APPENDIX

  • 27.1 ABBREVIATIONS